Efficacy of 4 Years of Octreotide Long-Acting Release Therapy in Patients with Severe Polycystic Liver Disease

Mayo Clinic Proceedings

Volumn 90, Issue 8, 2015, Pages 1030-1037

  Hogan, Marie C ^a   Masyuk, Tetyana ^a   Bergstralh, Eric ^a   Li, Bill ^a   Kremers, Walter K ^a   Vaughan, Lisa E ^a   Ihrke, Angela ^a   Severson, Amanda L ^a   Irazabal, Maria V ^a   Glockner, James ^a   Larusso, Nicholas F ^a   Torres, Vicente E ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; OCTREOTIDE; PLACEBO; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; DELAYED RELEASE FORMULATION;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FLATULENCE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GRANULOMA; HUMAN; INJECTION SITE PAIN; KIDNEY MASS; KIDNEY POLYCYSTIC DISEASE; LIVER POLYCYSTIC DISEASE; LIVER WEIGHT; LONG TERM CARE; LOOSE FECES; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; PROSPECTIVE STUDY; PROTHROMBIN TIME; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SHORT FORM 36; SKIN BRUISING; VITAL SIGN; CYSTS; DELAYED RELEASE FORMULATION; DRUG ADMINISTRATION; LIVER DISEASES; MALE; ORGAN SIZE; PATHOLOGY; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, HORMONAL; CYSTS; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; LIVER DISEASES; MALE; OCTREOTIDE; ORGAN SIZE; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84938746888     PISSN: 00256196     EISSN: 19425546     Source Type: Journal    
DOI: 10.1016/j.mayocp.2015.05.011     Document Type: Article

References (21)

1. K.T. Bae, F. Zhu, A.B. Chapman, and et al. Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort Clin J Am Soc Nephrol 1 1 2006 64 69
2. P. Ruggenenti, A. Remuzzi, P. Ondei, and et al. Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease Kidney Int 68 1 2005 206 216
3. A. Caroli, L. Antiga, M. Cafaro, and et al. Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide Clin J Am Soc Nephrol 5 5 2010 783 789
4. L. van Keimpema, F. Nevens, R. Vanslembrouck, and et al. Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial Gastroenterology 137 5 2009 1661 1668
5. M.C. Hogan, T.V. Masyuk, L.J. Page, and et al. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease J Am Soc Nephrol 21 6 2010 1052 1061
6. M.C. Hogan, T.V. Masyuk, L. Page, and et al. Somatostatin analog therapy for severe polycystic liver disease: results after 2 years Nephrol Dial Transplant 27 9 2012 3532 3539
7. A. Caroli, N. Perico, A. Perna, and et al. Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial Lancet 382 9903 2013 1485 1495
8. L. van Keimpema, R.A. de Man, and J.P. Drenth Somatostatin analogues reduce liver volume in polycystic liver disease Gut 57 9 2008 1338 1339
9. M. Chrispijn, F. Nevens, T.J. Gevers, and et al. The long-term outcome of patients with polycystic liver disease treated with lanreotide Aliment Pharmacol Ther 35 2 2012 266 274
10. R. Peces, E. Cuesta-Lopez, C. Peces, V. Perez-Duenas, C. Vega-Cabrera, and R. Selgas Octreotide reduces hepatic, renal and breast cystic volume in autosomal-dominant polycystic kidney disease Int Urol Nephrol 43 2 2011 565 569
11. S. Treille, J.M. Bailly, J. Van Cauter, F. Dehout, and B. Guillaume The use of lanreotide in polycystic kidney disease: a single-centre experience Case Rep Nephrol Urol 4 1 2014 18 24
12. M. Sallee, C. Rafat, J.R. Zahar, and et al. Cyst infections in patients with autosomal dominant polycystic kidney disease Clin J Am Soc Nephrol 4 7 2009 1183 1189
13. J.J. Grantham, V.E. Torres, A.B. Chapman, and et al. Volume progression in polycystic kidney disease N Engl J Med 354 20 2006 2122 2130
14. V.E. Torres, A.B. Chapman, O. Devuyst, and et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease N Engl J Med 367 25 2012 2407 2418
15. R. Haynes, N. Staplin, J. Emberson, and et al. Evaluating the contribution of the cause of kidney disease to prognosis in CKD: results from the Study of Heart and Renal Protection (SHARP) Am J Kidney Dis 64 1 2014 40 48
16. G.W. Bigg-Wither, K.K. Ho, R.R. Grunstein, C.E. Sullivan, and B.D. Doust Effects of long term octreotide on gall stone formation and gall bladder function BMJ 304 6842 1992 1611 1612
17. P.H. Davies, S.E. Stewart, L. Lancranjan, M.C. Sheppard, and P.M. Stewart Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly Clin Endocrinol (Oxf) 48 3 1998 311 316
18. K.Y. Ho, A.J. Weissberger, P. Marbach, and L. Lazarus Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreotide) in acromegaly: effects of dose and frequency and long-term safety Ann Intern Med 112 3 1990 173 181
19. A. Telenti, V.E. Torres, J.B. Gross Jr., R.E. Van Scoy, M.L. Brown, and R.R. Hattery Hepatic cyst infection in autosomal dominant polycystic kidney disease Mayo Clin Proc 65 7 1990 933 942
20. F. Jouret, R. Lhommel, O. Devuyst, and et al. Diagnosis of cyst infection in patients with autosomal dominant polycystic kidney disease: attributes and limitations of the current modalities Nephrol Dial Transplant 27 10 2012 3746 3751
21. M.A. Lantinga, J.P. Drenth, and T.J. Gevers Diagnostic criteria in renal and hepatic cyst infection Nephrol Dial Transplant 30 5 2015 744 751